End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.13295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Heather J Whitaker und 29 weiteren Autor:innen. Beteiligte Einrichtung: Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Primary Health Care, Influenza A Virus, H3N2 Subtype. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Health Security Agency, Public Health Scotland, Public Health Wales.
Abstract (Originalsprache)
Background
The 2022/23 influenza season in the United Kingdom saw the return of influenza to prepandemic levels following two seasons with low influenza activity. The early season was dominated by A(H3N2), with cocirculation of A(H1N1), reaching a peak late December 2022, while influenza B circulated at low levels during the latter part of the season. From September to March 2022/23, influenza vaccines were offered, free of charge, to all aged 2–13 (and 14–15 in Scotland and Wales), adults up to 49 years of age with clinical risk conditions and adults aged 50 and above across the mainland United Kingdom.
Methods
End‐of‐season adjusted vaccine effectiveness (VE) estimates against sentinel primary‐care attendance for influenza‐like illness, where influenza infection was laboratory confirmed, were calculated using the test negative design, adjusting for potential confounders.
Methods
Results In the mainland United Kingdom, end‐of‐season VE against all laboratory‐confirmed influenza for all those > 65 years of age, most of whom received adjuvanted quadrivalent vaccines, was 30% (95% CI: −6% to 54%). VE for those aged 18–64, who largely received cell‐based vaccines, was 47% (95% CI: 37%–56%). Overall VE for 2–17 year olds, predominantly receiving live attenuated vaccines, was 66% (95% CI: 53%–76%).
Conclusion
The paper provides evidence of moderate influenza VE in 2022/23.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Statistics, Modelling and Economics Department, UK Health Security Agency, London, UK.
- Clinical and Protecting Health, Public Health Scotland, Glasgow, UK.
- Public Health Wales Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, UK.
- Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
- Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK.
- Wales Specialist Virology Centre, Public Health Wales Microbiology, Cardiff, UK.
ORCID-Profile: Heather J Whitaker, Jana Zitha, Gavin Jamie, Beatrix Kele
Förderung
- UK Health Security Agency
- Public Health Scotland
- Public Health Wales
Zitieren
APA
Whitaker, H. J., Willam, N., Cottrell, S., Goudie, R., Andrews, N., Evans, J., Moore, C., Agrawal, U., Hassell, K., Gunson, R., Zitha, J., Anand, S., Sebastian-Pillai, P., Kalapotharakou, P., Okusi, C., Hoschler, K., Jamie, G., Kele, B., Hamilton, M., …, & Watson, C. H. (2024). End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13295
Vancouver
Whitaker HJ, Willam N, Cottrell S, Goudie R, Andrews N, Evans J, et al. End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13295
BibTeX
@article{Whitaker2024,
author = {Whitaker, Heather J and Willam, Naoma and Cottrell, Simon and Goudie, Rosalind and Andrews, Nick and Evans, Josie and Moore, Catherine and Agrawal, Utkarsh and Hassell, Katie and Gunson, Rory and Zitha, Jana and Anand, Sneha and Sebastian-Pillai, Praveen and Kalapotharakou, Panoraia and Okusi, Cecilia and Hoschler, Katja and Jamie, Gavin and Kele, Beatrix and Hamilton, Mark and Couzens, Anastasia and Quinot, Catherine and Pheasant, Kathleen and Byford, Rachel and Marsh, Kimberly and Robertson, Chris and de Lusignan, Simon and Williams, Christopher and Zambon, Maria and McMenamin, Jim and Watson, Conall H},
title = {End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.13295}
}
EUVIMED